Document is current
Any future updates will be listed below
-
Authors
Petersen, Jeff Zarp
Schmidt, Lejla Sjanic
Vinberg, Maj
Jørgensen, Martin Balslev
Hageman, Ida
Ehrenreich, Hannelore
Knudsen, Gitte Moos
Kessing, Lars Vedel
Miskowiak, Kamilla Woznica
-
Funding
Funding for this research was provided by:
Lundbeckfonden (R21520154121)
- License Information
-
More Information
Article History
Received: 2 November 2017
Accepted: 16 October 2018
First Online: 6 November 2018
Ethics approval and consent to participate
: The study has been approved by the Danish Medicines Agency (EudraCT number 2016–004023-24), the Ethics Committee in the Capital Region of Denmark (protocol number H-16043370), and The Danish Data Protection Agency Capital Region of Denmark (protocol number RHP-2017-020) and has been retrospectively registered atExternalRef removed(NCT03315897)ExternalRef removedon 20th October 2017. Any important protocol modifications will be reported to the Danish Medicines Agency, the Ethics Committee in the Capital Region of Denmark, and the Danish Data Protection Agency. Written informed consent has been and will be obtained from all participants.
: Not applicable.
: JZP, LSS, MBJ, and IH declare no competing interests. KWM has received consultancy fees from Lundbeck and Allergan. MV discloses consultancy fees from Lundbeck and Astra Zeneca within the last three years. GMK was supported by a Center grant from the Innovation Fond, Center for Experimental Medicine Neuropharmacology (Neuropharm). LVK reports having been a consultant for Lundbeck, AstraZeneca, and Sunovion within the last three years. HE holds user patents for EPO in stroke, schizophrenia, and MS.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
